Zalicus, formerly CombinatoRx, discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The Company applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for both internal product pipeline and its collaborators.